Given that targeting STAT3 by the STAT3 inhibitors such as C188-9 has been evaluated in early phase clinical trials for advanced-stage cancers (NCT03195699) (61–63), it should be taken into caution for the rational design of combinatorial approaches using chemotherapy to boost oncolytic NDV-induced ICD. This evidence concerns the gene STAT3 and cancer.